Ratings Molina Healthcare, Inc.

Equities

MOH

US60855R1005

Real-time Estimate Cboe BZX Other stock markets 03:56:50 2024-04-19 pm EDT			5-day change	1st Jan Change
367.5 ^USD	+1.81%		-2.11%	+2.02%

Apr. 15	Molina Healthcare Shares Down After Price Target Cuts	MT
Apr. 15	Wells Fargo Cuts Price Target on Molina Healthcare to $410 From $440, Keeps Equalweight Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The stock, which is currently worth 2024 to 0.44 times its sales, is clearly overvalued in comparison with peers.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.
In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
MOLINA HEALTHCARE, INC.	+2.02%	21.15B	B-
ELEVANCE HEALTH, INC.	+13.01%	122B	A-
CIGNA	+17.73%	98.93B	B-
CENTENE CORPORATION	+1.48%	39.45B	B-
HUMANA INC.	-28.21%	39.16B	A-
PROGYNY, INC.	-12.64%	3.06B	C+
ALIGNMENT HEALTHCARE, INC.	-39.49%	964M	B-
CLOVER HEALTH INVESTMENTS, CORP.	-34.43%	313M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes